HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Barnett, A. H. Search for Related Content PubMed Articles by Barnett, A. H. Social Bookmarking                What's this?

An Open, Randomized, Parallel-Group Study to Compare the Efficacy and Safety Profile of Inhaled Human Insulin (Exubera) With Glibenclamide as Adjunctive Therapy in Patients With Type 2 Diabetes Poorly Controlled on Metformin

Response to Kanna and Abreu-Pacheco

¹ University of Birmingham and Heart of England National Health Service Foundation Trust (Teaching), Birmingham, U.K
² Department of Diabetes and Metabolism, Bethanien Krankenhaus, Hamburg, Germany
³ Department of Respiratory Medicine, Hvidovre University Hospital, Hvidovre, Denmark
⁴ Pfizer Ltd., Sandwich, U.K

Address correspondence to A.H. Barnett, Undergraduate Centre, Birmingham Heartlands Hospital, Bordesley Green East, Birmingham, B9 5SS, U.K. E-mail: anthony.barnett@heartofengland.nhs.uk

The first 20% of the full text of this article appears below.

We thank Kanna and Abreu-Pacheco (1) for their comments on our study (2). As Kanna and Abreu-Pacheco point out, overweight and obesity are strongly linked to the development of type 2 diabetes and can complicate its management. While most patients with type 2 diabetes are overweight (3), this study (2) included individuals with a range of BMI values typical of those . . . [Full Text of this Article]

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				D. Cohen Hyperglycemia and Diabetes in Patients With Schizophrenia or Schizoaffective Disorders: Response to Jindal and Keshavan Diabetes Care, February 1, 2007; 30(2): 447 - 448. [Full Text] [PDF]